Sio Capital Management, LLC filed an amended Schedule 13G with the SEC on November 2, 2026, disclosing beneficial ownership of 2,000,000 shares of Serina Therapeutics, Inc. common stock as of September 30, 2026.

Key Highlights

  • Beneficial ownership: Sio Capital Management, LLC reported aggregate beneficial ownership of 2,000,000 shares of Serina Therapeutics common stock.
  • Percent of class: The 2,000,000 shares represent 7.87% of the class, based on 25,400,473 common shares outstanding as of August 10, 2026.
  • Voting and dispositive power: Sio Capital reported 0 sole voting power and 0 sole dispositive power, with 2,000,000 shares held under shared voting and shared dispositive power.
  • Control structure: Both Sio Capital Management, LLC and Sio GP, LLC are controlled by Michael Castor, who the filing states may be deemed to control voting and dispositive decisions over the reported shares.
  • Triggering event date: The date of event requiring this filing was September 30, 2026.
  • Filer type: Sio Capital Management, LLC is identified as a registered investment adviser (type "IA"), organized as a Delaware limited liability company.

Sio Capital Management's Amended 13G Position in Serina Therapeutics

According to the filing, Sio Capital Management, LLC submitted Amendment No. 1 to its Schedule 13G regarding its holdings in Serina Therapeutics, Inc., whose common stock carries a par value of $0.0001 per share and CUSIP number 81751A108. The event triggering the amended disclosure occurred on September 30, 2026. Serina Therapeutics is headquartered at 601 Genome Way, Suite 2001, Huntsville, AL 35806, according to the filing.

The filing states that Sio Capital Management acts as a registered investment adviser to certain affiliated funds that directly hold the shares of common stock, and that it has voting and dispositive power over such shares in that capacity. All 2,000,000 shares are reported under shared voting and shared dispositive power, with no shares held under sole voting or sole dispositive authority. The percent of class figure of 7.87% is based upon 25,400,473 common shares outstanding as of August 10, 2026, as disclosed in Serina Therapeutics' Form 10-Q filed August 13, 2026, according to the filing.

The filing further discloses that Sio GP, LLC serves as general partner to the same client funds, and that because Sio Capital Management's investment discretion is subject to oversight by Sio GP, LLC, the GP may be deemed a beneficial owner of the reported shares. The filing adds that both entities are controlled by Michael Castor, who may therefore be deemed to control the voting and dispositive decisions over the shares. However, the filing expressly states that "neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by the GP or Michael Castor that such person is the beneficial owner of any of the equity securities referred to herein for purposes of Section 13(d) of the Exchange Act."

What Was Disclosed

Sio Capital Management, LLC filed an amended Schedule 13G disclosing 2,000,000 shares, or 7.87%, of Serina Therapeutics common stock held with shared voting and dispositive power as of September 30, 2026, with the filing signed by Chief Compliance Officer Jin W. Lee on November 2, 2026.